Please use this identifier to cite or link to this item:
Title: Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model
Author: Sousa Pinto, Bernardo
Azevedo, Luís Filipe
Sá Sousa, Ana
Vieira, Rafael José
Amaral, Rita
Klimek, Ludger
Czarlewski, Wienczyslawa
Antó i Boqué, Josep Maria
Bedbrook, Anna
Kvedariene, Violeta
Ventura, Maria Teresa
Ansotegui, Ignacio
Bergmann, Karl Christian
Brussino, Luisa
Canonica, G. Walter
Cardona, Victoria
Carreiro Martins, Pedro
Casale, Thomas
Cecchi, Lorenzo
Chivato, Tomás
Chu, Derek K.
Cingi, Cemal
Costa, Elisio M.
Cruz, Alvaro A.
Feo, Giulia de
Devillier, Philippe
Fokkens, Wytske J.
Gaga, Mina
Gemicioglu, Bilun
Haahtela, Tari
Ivancevich, Juan Carlos
Ispayeva, Zhanat
Jutel, Marek
Kuna, Piotr
Kaidashev, Igor
Kraxner, Helga
Larenas Linnemann, Désirée E.
Laune, Daniel
Lipworth, Brian
Louis, Renaud
Mullol i Miret, Joaquim
Sastre, Joaquín
Keywords: Immunoteràpia
Issue Date: 28-Mar-2022
Publisher: Wiley
Abstract: Background Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air(R) app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods We assessed the MASK-air(R) data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales-VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = -12.1;-2.8), lower VAS Work (average difference = 5.0; 95%CrI = -8.5;-1.5), and a lower CSMS (average difference = 3.7; 95%CrI = -9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = -17.2;-2.8), lower VAS Work (average difference = 7.8; 95%CrI = -15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = -18.5;0.2). Conclusion In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its 'real-world' effectiveness.
Note: Reproducció del document publicat a:
It is part of: Clinical And Translational Allergy, 2022, vol. 12, num. 3
Related resource:
ISSN: 2045-7022
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
Allergen immunotherapy in MASK‐air users in real‐life Results of a_ClinTranslAllergy.pdf387.79 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons